substance p has been researched along with n-acetyltryptophan in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cernak, I; Cruz, MI; Donkin, JJ; Nimmo, AJ; Vink, R | 1 |
| Blumbergs, PC; Cernak, I; Donkin, JJ; Nimmo, AJ; Vink, R | 1 |
| Helps, SC; Thornton, E; Turner, RJ; Vink, R | 1 |
| Thornton, E; Vink, R | 1 |
| Carthew, HL; Vink, R; Ziebell, JM | 1 |
| Leonard, AV; Thornton, E; Vink, R | 1 |
| Friedlander, RM; Jiang, J; Li, W; Mao, LL; Sirianni, AC; Sugarbaker, P; Wang, X; Zeng, J; Zhang, X; Zhou, S | 1 |
7 other study(ies) available for substance p and n-acetyltryptophan
| Article | Year |
|---|---|
A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats.
Topics: Animals; Brain Injuries; Homeostasis; Magnesium; Magnesium Deficiency; Magnetic Resonance Spectroscopy; Male; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Substance P; Tryptophan | 2004 |
Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury.
Topics: Animals; Brain Edema; Brain Injuries; Capillary Permeability; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Immunohistochemistry; Magnetic Resonance Imaging; Male; Microscopy, Confocal; Microscopy, Immunoelectron; Motor Activity; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Substance P; Tryptophan | 2009 |
A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Infarction, Middle Cerebral Artery; Male; Neurokinin-1 Receptor Antagonists; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Recovery of Function; Substance P; Time Factors; Tryptophan | 2011 |
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cells; Dopaminergic Neurons; Inflammation; Male; Motor Activity; Neurokinin-1 Receptor Antagonists; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Substance P; Substantia Nigra; Tryptophan | 2012 |
Substance P-induced changes in cell genesis following diffuse traumatic brain injury.
Topics: Animals; Brain Injuries; Cell Differentiation; Male; Microglia; Neurogenesis; Neurokinin-1 Receptor Antagonists; Neuroprotective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Substance P; Tryptophan | 2012 |
NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Inflammation; Neurokinin-1 Receptor Antagonists; Protease Inhibitors; Rabbits; Receptors, Neurokinin-1; Spinal Cord Compression; Substance P; Tryptophan | 2014 |
N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Caspases; Cell Line; Cytochromes c; Drug Evaluation, Preclinical; Hybrid Cells; Interleukin-1beta; Mice; Mitochondria; Motor Neurons; Neurokinin-1 Receptor Antagonists; Neuroprotective Agents; Proteasome Endopeptidase Complex; Receptors, Neurokinin-1; Stereoisomerism; Substance P; Tryptophan | 2015 |